Скачать или смотреть Opus Genetics Unveils Breakthrough IRD Gene Therapy Research at 2025 Conferences

Discover the latest advancements in inherited retinal disease (IRD) gene therapy from Opus Genetics at major 2025 conferences. This video highlights:

Key presentations on gene & cell therapies for rare and common retinal diseases at the Ophthalmology Futures Forum in Paris.
One-year results from the Phase I/II trial of OPGx-LCA5 for LCA5-related retinal degeneration at RD 2025 in Prague.
Strategic insights on biotech maturation from the LSX World Congress in Boston.

Explore how Opus Genetics is leading the charge in AAV-based gene therapies for conditions like Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Learn about their pipeline, including OPGx-BEST1 and Phentolamine Ophthalmic Solution 0.75% for presbyopia and low-light vision challenges.

Stay updated on clinical-stage biopharmaceutical innovations and their impact on ophthalmic disorders. #IRD #GeneTherapy #OpusGenetics #RetinalDisease #BiotechInnovation